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        Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the 
United States and Europe. CLL patients with deletion of chromosome 17p, where the 
tumor suppressor p53 gene is located, often develop a more aggressive disease with 
poor clinical outcomes.  However, the underlying mechanism remains unclear. In order 
to understand the underneath mechanism in vivo, I have recently generated mice with 
Eu-TCL1-Tg:p53-/- genotype and showed that these mice develop aggressive leukemia 
that resembles human CLL with 17p deletion. The Eu-TCL1-Tg:p53-/- mice developed 
CLL disease at 3-4 months, significantly earlier than the parental Eu-TCL1-Tg mice 
that developed CLL disease at 8-12 months. Flow cytometry analysis showed that the 
CD5+/IgM+ cell population appeared in the peritoneal cavity, bone marrow, and the 
spleens of Eu-TCL1-Tg:p53-/- mice significantly earlier than that of the parental Eu-
TCL1-Tg mice. Massive infiltration and accumulation of leukemia cells were found in 
the spleen and peritoneal cavity of Eu-TCL1-Tg:p53-/- mice.  In vitro study showed that 
the leukemia cells isolated from the Eu-TCL1-Tg:p53-/- mice were more resistant to 
fludarabine treatment than the leukemia cells isolated from spleens of Eu-TCL1-Tg 
mice.  Interestingly, TUNEL assay revealed that there was higher apoptotic cell death 
found in the Eu-TCL1-Tg spleen tissue compared to the spleens of the Eu-TCL1-Tg:p53-
 V
/- mice, suggesting that the loss of p53 compromises the apoptotic process in vivo, and 
this might in part explain the drug resistant phenotype of CLL cells with 17p-deletion. 
In the present study, we further demonstrated that the p53 deficiency in the TCL1 
transgenic mice resulted in significant down-regulation of microRNAs miR-15a and 
miR16-1, associated with a substantial up-regulation of Mcl-1, suggesting that the p53-
miR15a/16-Mcl-1 axis may play an important role in CLL pathogenesis.  Interestingly, 
we also found that loss of p53 resulted in a significant decrease in expression of the 
miR-30 family especially miR-30d in leukemia lymphocytes from the Eu-TCL1-
Tg:p53-/- mice.  Such down-regulation of those microRNAs and up-regulation of Mcl-1 
were also found in primary leukemia cells from CLL patients with 17p deletion. To 
further examine the biological significance of the decrease in the miR-30 family in 
CLL, we investigated the potential involvement of EZH2 (enhancer of zeste homolog 
2), a component of the Polycomb repressive complex known to be a downstream target 
of miR-30d and plays a role in disease progression in several solid cancers. RT-PCR 
and western blot analyses showed that both EZH2 mRNA transcript and protein levels 
were significantly increased in the lymphocytes of Eu-TCL1-Tg:p53-/- mice relative to 
Eu-TCL1-Tg mice.  Exposure of leukemia cells isolated from Eu-TCL1-Tg:p53-/- mice 
to the EZH2 inhibitor 3-deazaneplanocin (DZNep) led to induction of apoptosis, 
suggesting EZH2 may play a role in promoting CLL cell survival and this may 
contribute to the aggressive phenotype of CLL with loss of p53.  Our study reveals that 
p53-miR15a/16-Mcl-1 axis & p53-miR30-EZH2 axis may contribute to the CLL 
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          1.1 Cellular origin(s) of chronic lymphocytic leukemia. Chronic 
lymphocytic leukemia (CLL) is the most common leukemia in the Western 
world and accounts for about 30% of all adult leukemia cases.  CLL is a disease 
of elderly people resulting from an accumulation of mature-looking neoplastic 
CD5+ B lymphocytes in primary & secondary lymphoid tissues, and CLL cells 
express CD19, CD23 and CD20 as well (1-3). Despite the fact that over past 
years several cell types have been suggested as giving rise to CLL, the cellular 
origin of CLL is still unclear (4).  The belief that the cellular origin of CLL is 
from follicular mantle B cells due to shared surface membrane expression of 
CD5 and CD23 was challenged by the DNA sequencing result showing that 
approximately 50% CLL cases have IGHV mutations, whereas follicular mantle 
B cells almost have unmutated  IGHVs (5, 6). Another belief that CLL clones 
with either mutated or unmutated IGHVs derived from marginal zone (MZ) B 
cells defined as IgMhighIgDlow cells as most CLL clones also faces difficulties 
because MZ B cells are CD5-CD23-CD22+ differing from CLL cells (7, 8). A 
single-cell origin of CLL was challenged by the evidence for remarkably similar 
B-cell receptor (BCR) amino acid sequence and striking differences in poly-
antigen and autoantigen-binding activity found in some CLL clones (9). The 
feature of CLL clones using either mutated or unmutated IGHV genes (M-CLL 
and U-CLL) gave rise to the hypothesis that 2 subgroups of CLL originated 
from distinct cell types considered as a 2-cell origin model (10, 11). However, 
the 2-cell origin model exhibited difficulties resulting from gene expression 
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profiling which revealed that only a relatively small number of genes have 
differences between U-CLL and M-CLL , whereas there are thousands of 
differences between normal B lymphocytes and either U-CLL or M-CLL (12). 
Therefore difference in cellular features between U-CLL and M-CLL could be 
explained by a sing-cell derivation with additional and nongenetic promoting 
factors. Regarding normal counterparts of CLL, leukemogenesis is at least a 
multistep process. In 2011, possibilities for single- and multiple-cell origin 
models offered by some researchers partially answered the question whether a 
single- or multiple normal counterparts of CLL were stimulated to evolve into 
CLL (9).  
         1.2 Genetic abnormalities in CLL. Fluorescence in situ hybridization 
(FISH) analysis has revealed that up to 80% of CLL cases exhibited 
chromosomal abnormalities such as deletions of 13q14 in 55% CLL cases, 11q 
deletion in 12%, 17p deletion in 8% and trisomy of chromosome 12 in 15% of 
CLL cases (13, 14). Among the chromosomal abnormalities, deletions at 13q14 
are the most frequent chromosomal abnormalities and present in more than half 
of CLL cases. Some of the cytogenetic changes are associated with poor 
prognosis and aggressive disease progression.  Chromosome 17p deletion (17p-) 
is the most recognized cytogenic alteration in CLL associated with aggressive 
disease progression, resistance to chemotherapy, and poor clinical outcome (15). 
Since the tumor suppressor p53 gene is located in human chromosome 17p (16), 
it is suspected that the loss of p53  function in CLL cells with 17p- may be 
responsible for the poor prognosis of this subgroup of CLL patients (17, 18). 
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Initially, TP53 was considered as an oncogene. However, since 1989 it has been 
found that p53 functions as a tumor suppressor and is frequently mutated in 
human cancers (19-21). More than half of human tumors have a p53 deletion or 
mutation (22). What is the p53 status in CLL? Mutations of TP53 are found in 
4% to 37% of patients with CLL (23). Patients with fludarabine-refractory CLL 
have the highest incidence of TP53 mutation (24). Interestingly, recent study 
suggested that a very high concordance (over 70%) in 17p-deletion and 
mutations in the remaining p53 allele (25).  Furthermore, p53 dysfunction may 
also arise via alternative mechanisms such as functional inactivation, which 
may explain certain CLL with poor prognosis but without apparent structural 
changes in p53 gene such as 17p-deletion or mutations (26).  Thus, it is clear 
that the loss of p53 function has profound effect on the CLL disease progress 
and treatment outcomes.  However, the underlying mechanisms remain to be 
elucidated.  
        1.3 CLL microenvironment. The microenvironment, a complication of 
accessory cells that within individual organs, provides  growth factors, nutrients 
and immune tolerance for the survival and propagation of malignant cells in 
solid tumors through cell-cell contact and active molecular crosstalk (27). In 
CLL, the interactions between the malignant cells and the microenvironment in 
vivo provide the proliferative drive for the malignant cells through the external 
signals from the microenvironment such as antigens, cytokines and cell-cell 
contact. In vitro, CLL cells undergo spontaneous apoptosis, suggesting that 
CLL cell survival depends on microenvironment signals (28, 29). There is 
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growing evidence suggesting that CLL cells are protected from spontaneous 
apoptosis and conventional drug in vitro by various stromal cells including 
mesenchymal marrow stromal cells (MSCs) (30, 31), monocyte-derived 
nurselike cells (NLCs) (30), and follicular dendritic cells (32) through co-
culture that partially mimics the CLL microenvironment.  Interactions between 
CLL cells and MSCs provide CLL survival and drug resistance by promoting 
CLL cell migration which depends on CXCR4 and VLA-4 expression by CLL 
cells (33). There are several common stromal cell lines used for protecting CLL 
cells through co-culture, including human stromal cell lines HS5 & NK Tert and 
mouse stromal cell line KUSA-H1. NLCs protect CLL cells from spontaneous 
apoptosis and conventional drugs through secreting CXCL12 (30), CXCL13 
(34), B cell-activating factor of the tumor necrosis factor (BAFF), CD31 and 
plexin-B (35). T cells play several roles in CLL. In one hand, some subsets of T 
cells may overcome the antitumor effect derived from other T-cell subsets and 
favor disease progression. In the other hand, the significant immune deficiency, 
which is typical in CLL, resulted from T-cell abnormalities (36, 37). The overall 
number of circulating T cells stimulate CLL cell growth and survival by 
secreting interleukin-4 (IL-4) and tumor necrosis factor- (TNF-) (27). 
         1.4 CLL treatment. CLL treatment includes chemotherapy with agents 
such as fludarabine, chlorambucil, and bendamustine (38). Fludarabine, a purine 
analog, generated a significant improvement in overall responses compared with 
chlorambucil, an alkylating agent, in the CLL treatment (39). Up to 37% of 
untreated patients with CLL do not respond to fludarabine treatment and up to 
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76% of patients with CLL become refractory to the fludarabine treatment (40). 
Fludarabine and chadribine in combination with cyclophosphamide are equally 
effective for progressive CLL. However, both combinations are not effective in 
patients with 17p13 deletion (41).  Bendamustine agent, a cytotoxic hybrid of an 
alkylating agent and a purine analog, has improved overall response rates (42). 
The major issue for the purine analog therapy is lack of response in patients 
with 17p- CLL. Histone deacetylase inhibitors (HDACIs) can induce acetylation 
of histone and nonhistone proteins (43). The HDACI, valproate (VPA), 
synergizes with purine analogues to induce apoptosis in CLL cells (44).  β-
Phenylethyl isothiocyanate (PEITC), which is a natural compound found in 
cruciferous vegetables, effectively eliminates fludarabine-resistant CLL cells 
through ROS accumulation and glutathione depletion (45). It could be possible 
that PEITC only or PEITC combined with other chemotherapy agents will take 
a big step in the CLL treatment. Recent studies have shown that the compound 
PEITC overcomes resistance to HDACI in human leukemia through redox 
modulation (46).  Despite the improvement of chemotherapy in CLL, relapse is 
frequent. Rituximab (anti-CD20), the first approved therapeutic antibody in 
cancer treatment, has been used in refractory CLL (47). Chemoimmunotherapy 
improves overall therapy in patients with CLL and alemtuzumab (anti-CD52) 
based chemoimmnotheray has improved responses in relapsed/refractory 
disease (38, 48). Recently protein kinases have been considered as therapeutic 
targets in CLL due to the fact that an imbalanced functional response of the B-
cell receptor (BCR) signaling axis results in the deregulation of gene expression 
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in CLL. Spleen tyrosine kinase (SYK) is critical for B-cell development and is 
essential for the survival and maintenance of malignant B cells (49, 50). SYK 
inhibition in human CLL cells led to the downregulation of Erk, Akt, and Mcl-1, 
demonstrating that SYK regulates CLL survival (51-53). Bruton tyrosine kinase 
(BTK) plays an essential role in B-cell signaling and development. BTK are 
overexpressed in CLL lymphocytes as compared with normal B lymphocytes at 
both protein and mRNA levels (54). Ibrutinib, a specific inhibitor of BTK, can 
disrupt tumor microenvironment interactions, inhibit cellular migration and 
adhesion and induce apoptosis in malignant B-cells (55). Despite those 
significant improvements and potential therapeutic strategies in clinic, CLL still 
remains an incurable disease. Novel therapeutic agents targeting different 
signaling pathways will bring a new way for the future treatment of CLL and   
fludarabine-resistant/refractory CLL.   
        1.5 Treatment resistance in CLL-the role of the p53 pathway. Despite 
the improvements of chemotherapy strategies by novel therapeutic agents or 
their combinations in the CLL treatment, relapse is frequent. The appearance of 
effective first-line chemoimmunotherapy such as retuximab in CLL improved 
the response rates for treatment-refractory patients. Genetic abnormalities such 
as 13q14 deletion, un-mutated IGHV gene status, 11q deletion, particularly 17p 
deletion seem to be more important in determining the treatment outcome than 
initial treatment choice (56-58). CLL patients with 17p deletion have been 
shown to poorly respond to conventional chemotherapies such as fludarabine 
(57), probably because that the remaining allele contains a TP53 mutation or 
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deletion in the most cases. Are CLL patients with TP53 mutation in the absence 
of 17p deletion resistant to chemotherapy? The answer is positive. TP53 
mutation without 17p deletion corresponds to the development of 
chemotherapy-resistant disease and is associated with poor survival (59). More 
than half of human tumors have a p53 deletion or mutation (22). Mutations of 
TP53 are found in 4% to 37% of patients with CLL (23). Patients with 
fludarabine-refractory CLL have the highest incidence of TP53 mutation (24). 
Taking together, p53 seems to play a central role in the drug resistance of CLL. 
         1.6 Animal models that resemble human CLL and underlying    
mechanisms. Animal model tools are important to investigate disease processes 
and associated pathological mechanisms in vivo.  Currently there are several 
CLL mouse models, which include the Eµ-TCL1 transgenic (TCL1-Tg) mice 
(60), the April transgenic mice (61), the TRAF2DN/bcl2 transgenic mice (62), 
the miR-155 mouse model (63), the NZB mouse model with miR-16 alteration 
(64), and the miR-29 transgenic mice (65), and so on. The TCL1-Tg mouse 
model, which was created by the insertion of the human TCL1 gene under the 
control of the immunoglobulin heavy chain variable region promoter and 
immunoglobulin heavy chain enhancer, represents a well characterized mouse 
model that develops leukemia resembling human CLL (60). Why TCL1 causes 
leukemia? TCL1 physically interacts with Akt through PH domain of Akt. This 
interaction enhances Akt kinase activity and promotes Akt nuclear translocation 
(66). It has been reported that transgenic mice expressing constitutively 
activated Akt in T cells develop T cell leukemia (67), whereas transgenic mice 
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expressed constitutively activated Akt in B cells do not develop B cell leukemia 
(68). Those reports suggest that Akt activation causes leukemia in T cells 
initiated by TCL1. However TCL1 deregulation in B cells causes CLL not 
through Akt activation. Overexpression of TCL1 in B cells causes CLL by 
enhancing NF-ĸB activity and inhibiting AP-1 (69). The TCL1-Tg mice develop 
human CLL-like disease at 8 to 12 months of age and exhibit features of human 
CLL with expanded IgM+CD5+ CLL population in peritoneal cavity (PC), 
spleen and bone marrow (60). The CLL cells isolated from TCL1-Tg mice 
undergo rapid cell turnover with high levels of proliferation and apoptosis (70). 
TCL1XBAFF-Tg mice generated by crossing TCL1-Tg with BAFF-Tg mice, 
which express high levels of CD257, develop CLL-like disease around 4.5 
months of age with more rapid disease progression and shorter survival that 
TCL1-Tg mice (70). BAFF and APRIL are recent members of TNF superfamily 
and show increased expression levels in various B cell malignancies. BAFF and 
APRIL bind to two receptors BCMA & TACI and stimulate NFĸB pathway 
through interactions with TRAFs, contributing to CLL pathogenesis in 
TCL1XBAFF-Tg mice and April transgenic mice (71). APRIL transgenic mice 
had increased white blood cell count and did not develop any hematopoietic 
malignancy probably due to lack of second hit such as TCL1 overexpression 
(61). It has been reported that miR-29 is upregulated in indolent human CLL 
with low ZAP-70 expression and mutated IGHV (72). MicroRNAs are 
regulatory non-coding RNAs with 20 to 25 nucleotides in length. The primary 
function of microRNAs is to target specific messenger RNA for degradation or 
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inhibition of translation, leading to downregulation of the target proteins (73, 
74). Recent studies have shown that the regulatory functions of microRNAs are 
involved in various cellular processes including development, differentiation, 
apoptosis, survival and metabolism (75, 76). It has been reported that 
microRNA signatures are associated with CLL progression and prognosis (77, 
78). Desregulation of some microRNAs have been viewed as a contributing 
factor for CLL apoptotic defect. For example, upregulated Bcl-2 resulted from 
downregulation of miR15a/16-1 (79). In 2006, Dr. Croce’s group reported that 
Eµ-miR155 transgenic mice develop a B cell malignancy with a preleukemic 
pre-B cell proliferation (63). In 2010, Dr. Croce’s group also reported that Eµ-
miR-29 transgenic mice develop a disease that resembles human indolent CLL 
phenotype probably through targeting TCL1 and Mcl-1 by miR-29 (80, 81). 
Previous studies have shown that over-expression of Bcl-2 family members 
occur in many cases of CLL and this is correlated with resistance to therapy and 
a poor prognosis (82). A constitutive increase of Bcl-2 through a deletion of 
miR-15a/16-1 cluster contributes to CLL pathogenesis (62). Bcl-2 transgenic 
mice showed polyclonal expansion of B cells and increased cell survival 
without developing any tumor (83). In contrast, most of TRAF2DN/Bcl2 double 
transgenic mice develop B cell leukemia resembling human CLL with severe 
splenomegaly and significant high number of white blood cells (62).  As 
mentioned before, TRAF2, a TNF receptor associated factor 2, interacts with 
TNF receptor family members such as BCMA and activates NF-ĸB and JNK 
signaling pathways (84). Although Bcl-2 or TRAF2 single transgenic mice 
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failed to develop any hematological malignancy, the TRAF2DN/Bcl2 double 
transgenic mice had rapid disease progression and developed human CLL-like 
disease over time and died at 6 to 14 months of age. NF-ĸB activation and 
overexpression of anti-apoptotic Bcl-2 could contribute to the disease 
progression in the TRAF2DN/Bcl2 double transgenic mice. Among the anti-
apoptotic members of Bcl-2 family, the myeloid cell leukemia-1 (Mcl-1) has 
been demonstrated as an important anti-apoptotic protein in CLL both in vitro 
and in vivo (85).  It has been shown that Mcl-1 promotes CLL cell survival by 
inhibiting the intrinsic Bak/Bax-mediated apoptotic pathway (86).  Loss of p53 
function in cancer cells has also been associated with decrease in apoptotic 
response and drug resistance (59), and mice with p53-/- genotype are highly 
susceptible to the development of a variety of tumors (87). However, currently 
it is unclear if there is a link between the loss of p53 and over-expression of 
Mcl-1 in CLL cells. As mentioned before, there is no doubt that the loss of p53 
function has profound effect on the CLL disease progress and treatment 
outcomes. However, there is no any animal model available for studying the 
effect of p53 deletion in CLL biology and pathogenesis. TCL1-Tg mouse model 
closely recapitulates human CLL disease. This mouse model can not be used to 
study CLL with p53 gene deletion. To generate an animal model that closely 
resembles human CLL patients with p53 deletion, we generated a mouse colony 
with TCL1 transgenic and p53-deletion (TCL1-Tg:p53-/-) genotype by crossing 
the TCL1-Tg mice with p53-/- mice. We hypothesized that loss of p53 causes 
rapid disease progression, treatment resistance and shorter survival time in 
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TCL1-Tg mice by modulating CLL cell proliferation and apoptosis. Our 
preliminary data showed that the TCL1-Tg:p53-/- mice develop leukemia that 
resembles human aggressive CLL disease around 3-4 months. The leukemia 
cells from TCL1-Tg:p53-/- mice exhibited higher proliferation, higher survival 
capacity, and more resistant to drug treatment with fludarabine than the 
leukemia cells from the TCL1 transgenic mice with wild-type p53.  We further 
demonstrated that the loss of p53 led to a significant increase of Mcl-1 
expression, likely through the expression of miR-15a and miR-16-1 expression.  
Our microRNA array data showed significant downregulation of miR15a/16-1, 
miR-30a, miR-30d and miR-30e, especially miR-30d, in both human and mouse 
CLL cells with p53 deficiency, and such downregulation of those microRNAs 
were confirmed by RT-PCR. As mentioned before, mir-15a and miR-16-1, 
located at 13q14, were deleted or downregulated in approximately 66% CLL 
cases (88). Recent studies have shown that the miR15a/16-1 cluster function as 
tumor suppressor by targeting Bcl-2, Mcl-1, CCND1 and WNT3A (89). The 
association between the loss of p53, the decrease in miR15a/16-1 and the 
increase in Mcl-1 was further confirmed in primary leukemia cells from CLL 
patients with chromosome 17p deletion. The role of miR30 family in CLL is 
still unknown. It has been reported that miR-30d targets the polycomb protein 
enhancer of zeste 2 (EZH2) which is involved in repressing gene expression 
through methylation of histone H3 on lysine 27 and upregulated in anaplastic 
thyroid carcinomas (90). Over years, many studies have established that EZH2 
is overexpressed in various cancers including some hematologic malignancies, 
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and such overexpression is associated with aggressiveness and progression (91, 
92). DZNep, an S-adenosylhomocysteine hydrolase inhibitor, induce apoptosis 
in cancer cells such as AML through inhibiting S-adenosyl-L-methionine-
dependent methyltransferases such as EZH2 (93). A recent report showed a 
therapeutic strategy for lymphoma with EZH2-activating mutations through 
EZH2 inhibition (94). The role of EZH2 in CLL has yet to be examined in vitro 
and in vivo. Another target of miR-30 is B-Myb, which expression can be 
regulated by miR-30 and miR-29 during cellular senescence (95). B-Myb, a 
transcription factor, is involved in cell proliferation and transcription and 
carcinogenesis. B-Myb overexpression presents in various cancers and is 
associated with aggressive tumor growth and poor outcomes (96-98). However, 
the role of B-Myb in CLL is still unknown. This study provides in vivo evidence 
to support that p53miR15a/16Mcl-1 & p53miR30d EZH2 & B-Myb 
axis may contribute to the pathogenesis of aggressive CLL.  
 
 
2. SPECIFIC AIMS 
        Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in 
Western countries, and the disease is very heterogeneous in disease progression 
and response to drug treatment. Genetic aberrations such as chromosome 
deletion or gene mutation are frequently observed in CLL (99). A subtype of 
CLL with chromosome 17p deletion is associated with accelerated disease 
progression, drug resistance, and poor prognosis due to loss of p53 gene (100). 
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The subtype of CLL patients with 17p deletion or with TP53 mutations have 
much shorter survival time than other CLL patients without 17p deletion and 
TP53 mutations (101) . To develop efficient therapeutics for the CLL subtype 
with 17p deletion or TP53 mutations, it is critical to understand how exactly 
loss of p53 contributes to CLL disease progression and drug resistance.     
MicroRNAs (miRNAs), a group of short non-coding RNA molecules, regulate 
target gene expression via translational repression or transcriptional degradation 
(74). Several miRNAs such as miR-15a, miR-16 and miR-34a have been 
implicated in CLL pathogenesis and prognosis (102, 103). Interestingly, p53 
can upregulate miR-34 gene and miR-34 overexpression in turn induces 
senescence, apoptosis or cell cycle arrest by regulating proteins such as Bcl-2, 
Cyclin D1, CDK4 and c-MYC etc (104). Moreover, deregulated miRNA 
expression also mediates drug resistance in CLL patients with 17p deletion 
(105-109). Overall, p53 and miRNAs have been closely linked in CLL 
pathogenesis and prognosis. However, it remains unclear how loss of p53 
affects miRNAs and alters the regulatory function of miRNAs in CLL. As 
mentioned before, the TCL1-Tg mice develop human CLL-like disease at 8 to 
12 months of age with expansion of IgM+/CD5+ CLL population in PC, spleen 
and bone marrow (60). However, this TCL1-Tg mouse model can not be used to 
study the effect of p53 deficiency in CLL pathogenesis and microRNA 
deregulation. Therefore, we hypothesized that loss of p53 causes rapid disease 
progression and shorter survival time in TCL1-Tg mice by modulating CLL cell 
proliferation and apoptosis. To address this hypothesis, the TCL1-Tg:p53-/- 
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mouse model is generated by our group. This model is expected to be a good 
research model for providing potential therapeutic strategies and novel 
chemotherapies in the treatment of CLL subtype with 17p deletion, and for 
studying CLL biology and pathogenesis. It is also anticipated that the proposed 
studies will bring new insights into the relationship between loss of p53 and 
microRNA deregulation in CLL. In the proposed studies, 3 specific aims will be 
accomplished to address the hypothesis. 
        Specific Aim 1: Generation and characterization of TCL1-Tg:p53-/-  
mice.     
   General strategy. TCL1-Tg homozygous mice (B6C3 mice) were provided 
by Dr. Carlo M. Croce.  They are crossed with p53-/- mice (B6C3) which were 
from Jennifer Alana (a microinjection specialist in MDACC). Then the second 
generation of TCL1-Tg:p53+/- mice were intercrossed  to get  TCL1-Tg:p53-/-  
CLL mouse model. Afterwards, TCL1-Tg:p53-/- mice were intercrossed with 
each other to obtain pure TCL1-Tg:p53-/- mice for research studies (Figure 1). 
All mice were housed under conventional barrier protection in accordance with 
University of Texas MD Anderson Cancer Center guidelines, and mouse 
protocols were approved by University of Texas MD Anderson Cancer Center 
Institutional Animal Care and Use Committee.  
        Validation of p53 deletion and TCL1 overexpression in TCL1-Tg:p53-/-  
mice. Prior to any phenotypic analysis, the mice are genotyped for TCL1 
transgene and p53 mutant alleles. Furthermore, to confirm the inactivation of 
p53 protein expression, Western blot analysis of p53 will be performed using 
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splenocytes and peritoneal cavity cells from mice with respective genotypes. 
The TCL1-Tg mice don’t develop CLL disease until 13 months old, and p53-/- 
mice may develop tumors at 6 months old. Most of TCL1-Tg:p53-/- are fertile 
and we don’t expect any embryonic lethality or pup survival problem of these 
mice. Indeed, we have obtained the TCL1-Tg:p53-/- mice in the laboratory. 
        Characterization of CLL phenotype of TCL1-Tg:p53-/- mice. The TCL1-
Tg mice develop CLL disease featured by CD5+ B cell accumulation in bone 
marrow, spleen, and PC. To determine the percentage of CD5+ B cells at 
different ages, I will isolate cells from bone marrow, spleen, and peritoneal 
cavity of mice with difference genotypes at 2 month, 4months, 5 months, 7 
months of age, and perform FACS analysis using anti-CD5 and anti-IgM 
antibodies.  Meanwhile, blood smear will be performed to monitor white blood 
cell expansion in these mice at different ages. To further characterize the 
phenotype of the TCL1-Tg:p53-/- mice, Hematoxylin and eosin (H&E) staining 
of mouse tissues such as spleen and liver will be performed. Mouse survival 
will be monitored for three groups of mice for up to 2 years and each group 
contains more than 20 mice.  
        Specific Aim 2: Determine the effect of p53 deficiency on proliferation 
and apoptosis of splenocytes and investigate underlying mechanisms.  
        Determine p53 deficiency on proliferation and apoptosis of splenocytes. 
For years, CLL has been viewed as a tumor with low level of cell turn over. 
Consistently anti-apoptotic Bcl-2 family members are overexpressed in most 
CLL cases (82). Recently it was found that CLL cells from TCL1-Tg mice 
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undergo rapid cell turnover that can be offset by extrinsic CD257 to favor 
disease progression (70). We expect that p53 deficiency will accelerate CLL 
disease progression in TCL1-Tg mice by modulating cell proliferation and 
apoptosis. One of the complications of CLL is an enlarged spleen called 
splenomegaly. To determine the effect of p53 deficiency on cell proliferation, 
Bromodeoxyuridine (BrdU), a synthetic thymidine analog, incorporation assay 
will be performed for splenocytes isolated from p53-/- mice, TCL1-Tg mice, 
TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice. To further confirm the proliferation 
result, Ki67 (a proliferation marker) staining of spleen isolated from different 
types of mice will be performed. To determine the effect of p53 deficiency on 
apoptosis of splenocytes, Annexin V/Propidium Iodide (PI) staining will be 
performed for splenocytes isolated from p53-/- mice, TCL1-Tg mice, TCL1-
Tg:p53+/- and TCL1-Tg:p53-/- mice at 0, 24h and 72h after isolation. Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay will be 
performed on spleen tissues isolated from different types of mice to confirm the 
apoptosis results obtained from the Annexin-V/PI analysis.  
        Investigate the mechanistic link between p53 deficiency and altered 
proliferation & apoptosis rates of splenocytes. P53 functions as a 
transcription factor and regulates the expression of a number of genes involved 
in cell-cycle arrest, apoptosis and senescence (21, 110).  P53 is either mutated 
or deleted in more than 50% of human cancers and plays an tumor suppressor 
role in cancer (22). However, it is unknown how loss of p53 affects altered 
proliferation & apoptosis and pathogenesis in CLL. It has been reported that 
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anti-apoptotic Bcl-2 family members are overexpressed in most CLL cases, 
which is associated with chemotherapy resistance and poor prognosis (82). 
Particularly Mcl-1 plays an important role for CLL survival in both in vitro and 
in vivo (85). We first determine the expression of anti-apoptotic Bcl-2 family 
members in mouse splenocytes and PC cells by Western blot analysis at protein 
levels. PCR experiments will be also performed to determine the mRNA levels 
of anti-apoptotic Bcl-2 family members. Both protein and mRNA levels of anti-
apoptotic Bcl-2 family members will also be determined in human CLL patient 
samples with 17p deletion or without 17p deletion. We expect elevated 
expression levels of anti-apoptotic Bcl-2 family members in CLL cells with p53 
deficiency compared to CLL cells with p53 wt. How does p53 deficiency cause 
alteration of anti-apoptotic Bcl-2 family members? It could be through 
microRNA regulation. Several miRNAs such as miR-15a, miR-16 and miR-34a 
have been implicated in CLL pathogenesis and prognosis (102, 103). However, 
it remains unclear how loss of p53 affects miRNAs and alters the regulatory 
function of miRNAs in CLL. To address that question, miRNA array will be 
performed for both mouse and human RNA samples with p53wt or p53 
deficiency. Regard the array data, RT-PCR experiments need to be performed to 
confirm those miRNA alterations. Those miRNA targets observed may explain 
the alteration of anti-apoptotic Bcl-2 family members in mouse and human CLL 
cells with p53 deficiency. The mRNA and protein levels of other downstream 
molecules of those miRNAs will be determined by Western blot analysis 
respectively. To further confirm that p53 regulates those miRNAs, p53 will be 
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knocked down in some B cell lines such as EBVB. Then the expression of those 
miRNAs, Bcl-2 family and the downstream molecules of miRNAs will be 
determined in the B cell lines with p53 knock-down. In summary, we expect 
that p53 deficiency regulates some specific miRNAs which resulted in 
upregulation of anti-apoptotic Bcl-2 family members, leading to 
hyperperliferation, reduced apoptosis and rapid disease progression in TCL1-Tg 
mice.  
        Specific Aim 3: Determine the effect of p53 deficiency on CLL 
treatment response on cellular level and animal level. As mentioned in the 
introduction part, CLL patients with 17 deletion or TP53 mutation are resistant 
to conventional chemotherapies in the CLL treatment. To confirm that, CLL 
patient samples with or without 17p deletion will be appropriately treated with 
conventional chemotherapies such as fludarabine, chlorambucil and so on. 48h 
later, Annexin-V/PI analysis will be performed for those treated cells to detect 
apoptosis. Annexin-V/PI analysis will be also performed for similarly treated 
mouse splenocytes isolated from p53-/- mice, TCL1-Tg mice, TCL1-Tg:p53+/- 
and TCL1-Tg:p53-/- mice. We expect that both human CLL cells with 17p 
deletion and mouse CLL cells with p53 deficiency are resistant to those 
conventional chemotherapies. To overcome the treatment resistance of CLL 
cells with p53 deficiency, a novel chemotherapy agent-NL-101 is studied in the 
CLL treatment. NL-101 contains suberoylanilide hydroxamic acid (SAHA) and 
Bendamustine moieties in 1:1 ration. We hypothesized that HDACI such as 
SAHA can overcome the resistance of alkylating agents such as bendamustine 
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by reducing CLL migration to the microenvironment and induce more DNA 
damage than alkylating agents on CLL cells. Recent studies have shown that 
SAHA induces apoptosis in CLL by downregulating the CXCR4 chemokine 
receptor, leading to impaired migration of CLL cells (111).  Human CLL cells 
with 17p deletion or without 17p deletion will be treated with single agents such 
as NL-101, bendamustine, chlorambucil, SAHA or their combinations for 48h, 
and followed by Annexin-V/PI analysis. To investigate underlying mechanisms 
of the novel agent NL-101 on CLL treatment, the expression levels of cytokines 
in stromal cell lines treated with HDACI such as SAHA will be determined by 
RT-PCR, and followed by Enzyme-linked immunosorbent assay (ELISA) assay. 
Comet assay will be performed to determine DNA damage rate in CLL cells 
treated with SAHA, bendamustine, SAHA+Bendamustine and NL-101. We 
expect that HDACIs will reduce some cytokine levels such as CXCL12 secreted 
in stromal cell lines. We also expect more DNA damage caused by NL-101 or 
SAHA+bendamustine than single bendamustine treatment on CLL cells. PEITC 
can effectively eliminate fludarabine-resistant CLL cells through ROS 
accumulation and glutathione depletion (45). Therefore, we will try PEITC 
treatment or combination with other chemotherapies in both human and mouse 
CLL cells with or without p53 deficiency. To determine the effect of p53 
deficiency on CLL treatment response on animal level, 20 TCL1-Tg:p53-/- mice 
will be treated with nano-PEITC weekly through iv injection. Another 20 TCL1-
Tg:p53-/- mice will be treated with NL-101 2 times/month through iv injection. 
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We expect that both PEITC and NL101 will prolong the survival time of TCL1-
Tg:p53-/- mice.  
      In summary, the major objective of the proposed researches is to establish a 
CLL mouse model with p53 deficiency. This TCL1-Tg:p53-/-  mouse model will 
be utilized for testing novel therapeutic strategies and studying the effect of p53 
deficiency on CLL biology and pathogenesis. These proposed studies will 
provide new insights into how p53 deficiency affects expression of some 


















































Figure 1. Generation of TCL1-Tg:p53-/- mice.    TCL1-Tg homozygous mice are 
crossed with p53-/- mice. Then the second generation of TCL1-Tg:p53+/- mice 
are intercrossed  to get  TCL1-Tg:p53-/- mice,  TCL1-Tg:p53+/- mice, TCL1-









 3. MATERIAL AND METHODS    
                           3.1 Generation of TCL1-Tg:p53-/- mice.    TCL1-Tg mice (B6C3) were 
kindly provided by Dr. Carlo M. Croce.  They were crossed with p53-/- mice 
(B6C3) which were from Jennifer Alana (a microinjection specialist in MD 
Anderson Cancer Center). Then the second generation of TCL1-Tg:p53+/- mice 
were intercrossed  to get  TCL1-Tg:p53-/- CLL mouse model. For research 
studies, pure TCL1-Tg:p53-/- mice were obtained by intercrossing TCL1-Tg:p53-
/- mice (Figure 1). All mice were housed under conventional barrier protection 
in accordance with University of Texas MD Anderson Cancer Center guidelines, 
and mouse protocols were approved by the University of Texas MD Anderson 
Cancer Center Institutional Animal Care Committee. Survival data were 
obtained by observing mice up to 2 years (n=33 for TCL1-Tg:p53-/- mice and 
n=20 for TCL1-Tg mice). For mouse genotyping, small segments of mouse tail 
tips were collected from littermates at the age of 3-4 weeks, and were digested 
in 200 µL direct PCR lysis reagent with 5 µL proteinase K at 56ºC in a water 
bath for overnight, followed by a 5-minute incubation at 95ºC and then cooled 
on ice. After removal of tissue debris by centrifugation, 2 µL supernatant was 
used in a PCR reaction for genotyping. All primers were purchased from Sigma.        
        3.2 Blood smear. Around 250 µL    blood/mouse was collected from mouse 
tail of 5 mice for each genotype and put in an EDTA-coated tube. All blood 
samples were mixed well upon collection. Complete Blood Count (CBC) 
service and WBC differential count service were provided by Department of 
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Veterinary Medicine & Surgery Section of Veterinary Laboratory Medicine in 
MD Anderson Cancer Center.  
          3.3 Histopathology. Mouse spleen, liver and lymph node tissues from 6 
mice of each type were fixed in neutral buffered 10% formalin solution. After 
24h, the tissues were transferred to 70% alcohol. Within 3 months after fixation 
in 70% alcohol, the fixed tissues were sent to the histology core laboratory in 
MD Anderson Cancer Center for preparing histology slides.  Extra sections of 
the tissues were embedded in paraffin.  Sections were stained with hematoxylin 
and eosin (H&E) or Ki67 by the histology core laboratory in MD Anderson 
Cancer Center. H&E stained tissue slides were analyzed by Dr. Hesham M. 
Amin from the department of hematopathology in MD Anderson Cancer Center. 
        3.4 Polymerase Chain Reaction (PCR). For mouse genotyping, TCL1 
and p53 DNA contents were amplified using their specific primers. The TCL1 
DNA amplifying protocol was provided by Dr. Croce’s group. Primers for 
TCL1 are: sense, 5’GCCGAGTGCCCGACACTC3’ and antisense, 
5’CATCTGGCAGCAGCTCGA3’ The PCR using TCL1 primers was 
conducted at 94°C for 5 min for an initial denaturation step followed by 30 
cycles for 30 sec of denaturation at 94°C, 30 sec of annealing at 65°C, and 30 
sec of extension at 72°C, and a final extension step of 7 min at 72°C. The p53 
DNA amplifying protocol was provided by Chad Smith (Transgenic Core 
Facility of MD Anderson Cancer Center).  Primers for p53 are: p53-X7, 
5’GGATGGTGGTATACTCAGAGCC3’, p53-X6, 
5’AGCGTGGTGGTACCTTATGAGC3’ and neo19, 
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5’GCTATCAGGACATAGCGTTGGC3’. The PCR for amplifying p53 was 
performed at 95°C for 5 min for an initial denaturation process followed by 35 
cycles for 1 min of denaturation at 95°C, 1min of annealing at 60-62°C, and 3 
min of extension at 72°C, and a final extension step of 7 min at 72°C. The PCR 
results are ready for DNA gel electrophoresis or saved at -20°C. 1.8% agarose 
gel was prepared for electrophoresis. After DNA gel electrophoresis, the PCR 
results were separated on agarose gel and visualized on alpha-imager. 
        3.5 Isolation of CLL cells and cytotoxicity assays. Primary leukemia 
cells were isolated from the peripheral blood samples of CLL patients 
diagnosed according to the NCI criteria (112).  Proper informed consents under 
a research protocol approved by the Institutional Review Board (IRB) of MD 
Anderson Cancer Center were obtained from all patients before the collection of 
blood samples.  Specimens from CLL patients with or without 17p deletion 
were all used for comparison.  CLL cells were isolated from blood samples by 
density gradient centrifugation as described previously (45), and incubated in 
RPMI 1640 medium supplemented with 10% FBS and Penicillin (100 U/ml) + 
Streptomycin (100 ug/ml) overnight before testing drug sensitivity by 
incubation with CLL chemotherapies such as fludarabine. PC cells and 
splenocytes were isolated and treated with ACK cell lysis buffer for 2 minutes 
on ice to remove red blood cells. After lysis, RPMI medium with 10% FBS was 
added to the cells to stop the lysis. Afterwards, the cells were washed once by 
PBS and filtered through cell strainer with 40 µM nylon mesh (Fisher Scientific, 
Pittsburgh, PA) for single cell preparation and cultured in the same medium as 
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human CLL cells. B cells were purified from CLL cells by using CD19 
microbeads, and incubated in RPMI 1640 medium supplemented with 10% FBS 
and Penicillin (100 U/ml) + Streptomycin (100 ug/ml). At the same day, those B 
cells were treated with fludarabine or oxaliplatin for 48h.   Cell viability and 
cellular sensitivity to drug treatment in vitro were determined by flow 
cytometry after double staining of 1x106 cells with annexinV-fluorescein 
isothiocyanate (FITC) and PI analysis. 
          3.6 Reagents. 9--D-arabinofuranosyl-2-fluoro-adenine (F-ara-A, the 
nucleoside form of fludarabine), oxaliplatin, SAHA, PEITC, chlorambucil, 3-
DZNep, PI and PCR primers were purchased from Sigma-Aldrich (St. Louis, 
MO). Direct PCR lysis reagent was purchased from Viagen Biotech Inc. (Los 
Angeles, CA). ACK lysis buffer was from Lonza Houston, Inc. (Houston, TX). 
Ficoll-lite Lympho H (Fico) was from Atlanta Biological (Lawrenceville, GA). 
CD19 microbeads were purchased from MACS Miltenyi Biotech Inc. (Auburn, 
CA).  Annexin V-FITC was from BD Biosciences (San Jose, CA). NL-101 
compound was from Northlake Biosciences LLC (Lexington, MA). TUNEL 
staining kit was obtained from Roche Applied Science (Indianapolis, IN). 
Antibodies against Bcl-XL, Bcl-2, EZH2 and-actin were purchased from Cell 
Signaling Technology Inc. (Danvers, MA). Anti-b-Myb antibody was from 
EMD Millipore (Billerica, MA). Anti-Mcl1 antibody was from Santa Cruz 
Biotechnology (Santa Cruz, CA). 
        3.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR). 
Total RNA from 1X107 splenocytes isolated from TCL1-Tg, TCL1-Tg:p53+/- 
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and TCL1-Tg:p53-/- mice (4 for each genotype), were extracted, purified 
( RNeasy Mini kit, Qiagen) and quatified by Ultrospec 3300 pro UV/visible 
spectrophotometer. First-strand cDNA was synthesized from 0.5 µg total RNA 
by using a commercial kit (RevertAid First Strand cDNA Synthesis Kit-
Fermentas) according to the manufacturer’ instructions. Real-time PCR was 
performed with 7900 GT Sequence Detection System (ABI PRISM). All human 
and mouse primers for Bcl-XL, Mcl-1, Bcl-2, EZH2, b-Myb and CXCL12 were 
purchased from Sigma. Each PCR was performed in a 25-µL volume on a 96-
well optical plate for 2 minutes at 50ºC, followed by 10 minutes at 95ºC, then 
followed by 40 cycles of 95ºC for 30 seconds, 60ºC for 30 seconds and 72ºC for 
1minute and followed by 10 minutes at 72ºC. To independently validate the 
individual miRNA expression pattern from the miRNA array result, total RNA 
was isolated from patient white blood cells, and spleen cells from TCL1-Tg, 
TCL1-Tg:p53+/-  and TCL1-Tg:p53-/- mice by using miRNA isolation kit 
(Ambion). Then cDNA synthesis was carried out using Taqman MiRNA 
Reverse Transcription kit and specific Taqman RT primers (Applied 
Biosystems). MiRNA-specific real-time PCRs were performed using Taqman 
Universal PCR Master Mix and Taqman small assays according to the 
manufacturer’s protocol. The relative expression of specific miRNAs was 
calculated by the delta (deltaCt) method. 
         3.8 Immunoblotting. Primary CLL cells were isolated from patient blood 
using Fico as described above. Mouse splenocytes and PC cells were purified 
by ACK lysis buffer. B cells were purified by CD19 microbeads. Cell number 
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was determined by a Coulter Z2 particle count and size analyzer (Beckman 
Coulter, Inc., Fullerton, CA). The mouse splenocytes/PC cells or human CLL 
cells /B cells with same amount were then lysed in protein lysis buffer 
containing a cocktail of protease inhibitors. The nuclei and cell debris were 
removed by centrifugation at 4°C (13,000 rpm for 5 min), and the supernatants 
were collected as protein lysates. The protein lysates were then heated at 95°C 
for 5-15 min and separated by SDS-PAGE followed by Western blot analyses 
with antibodies specific for Bcl-XL, Mcl-1, Bcl-2, EZH2 and B-Myb. 
        3.9 Flow cytometry. Single-cell suspensions were made from mouse 
spleen, bone marrow and PC as described above, and stained for surface 
expression with FITC-labeled anti-IgM, allophycocyanin (APC)-labeled anti-
CD5 antibodies (Ebioscience, San Diego, CA). Annexin V and propidium 
iodide (PI) were used to monitor cell death. 
          3.10 Cell lines and cell culture. Stromal cell lines including human 
stromal cell lines NKTert & HS5 and mouse stromal cell line Kusa.H1, EBVB 
and Raji were cultured in RPMI 1640 medium supplemented with 10% FBS. 
Human white blood cells were isolated from CLL patients’ blood using Fico 
and cultured in RPMI 1640 medium supplemented with 10% FBS and Penicillin 
(100 U/ml) + Streptomycin (100 ug/ml) (PS). Mouse splenocytes were cultured 
in the same medium as used for human CLL cells. If co-culture applied, human 
CLL cells and mouse splenocytes were co-cultured with appropriate amount of 
stromal cells in 24-well plates one day before treatment with chemotherapies. 
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        3.11 Analysis of cell proliferation and apoptosis. Mouse spleen sections 
were fixed in neutral buffered 10% formalin solution for 24h and then incubated 
in 70% alcohol. The fixed tissues were sent to the histology core laboratory in 
MD Anderson Cancer Center for preparing histology slides. Cell proliferation 
was estimated by Ki67 immunostaining using Ki67 specific antibody and a 
horseradish peroxidast (HRP)-conjugated secondary antibody to reveal the 
diaminobenzidine (DAB) staining (Ki67 staining service ordered from the 
histology lab in MD Anderson Cancer Center). Terminal deoxynucleotidyl 
transferase deoxyuridine-triphosphatase nick-end labeling (TUNEL) assays 
were performed with an In Situ Cell Death Detection kit (Roche Applied 
Science, Indianapolis, IN) according to manufacturer’s instruction and 
visualized under fluorescent microscopy. Annexin-V/PI double-staining and 
flow cytometry analysis were used to monitor cell death.  
        3.12 Enzyme-linked immunosorbent assay (ELISA). SDF-1α (CXCL12) 
ELISA kit was purchased from Fisher Scientific (Pittsburgh, PA). CXCL12 
levels in drug treated NKTert, Kusa.H1 and HS5 stromal cells were determined 
by ELISA assay according to manufacturer’s instruction.  
        3.13 Comet assay. 5X106 human CLL cells were treated with 3µM SAHA, 
3µM NL-101, 10µM bendamustine and 3µM SAHA+10µM bendamustine for 
24h. The cells were collected and mixed with 37°C Low Melting Poit (LMP) 
agarose in dark. Then the cells were placed onto slides with coverslip for 5 min. 
The slides were put into cold, freshly made lysing solution at 4°C for at least 1h. 
The slides were gently removed from the lysing solution and briefly rinsed with 
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neutralization buffer, and put in alkaline butter for 15 min in dark to allow for 
unwinding of the DNA and expression of alkali-labile damage. Electrophoresis 
was performed for the slides at 25v/300mA for 20 min. After electrophoresis, 
the slides were dropwisely added neutralization buffer for 5 min and drained, 
and coated with cold 100% ethanol and allowed drying. The dry slides were 
stained with SYBR green and visualized under the fluorescent microscope. 
Those slides were rinsed in 100% ethanol and stored after drying. 
        3.14 Statistical analysis. Student t tests were used for testing the statistical 
difference between two groups of samples.  Mouse survival curves by Kaplan-
Meier plots were generated by Graphpad Prism software (GraphPad, San Diego, 
CA), and the statistical significance was analyzed by the log-rank (Mantel-Cox) 
test.  A p value of less than 0.05 was considered statistically significant. 
 
4. RESULTS 
          4.1 TCL1-Tg:p53-/- mice develop aggressive CLL with early disease 
onset and short lifespan. P53 is one of the most frequently mutated genes in 
cancers (22).  In human B-CLL, loss of p53 function has been associated with 
accelerated disease progression, poor prognosis, and resistance to antitumor 
agents (17, 113). Currently there is no CLL mouse model with loss of p53 for 
investigating the pathological process of this aggressive CLL.  To create such a 
animal model, we used the well-characterized TCL1 Transgenic CLL mice with 
p53wt to cross breed with p53-/- mice to generate progenies harboring TCL1-
Tg:p53-/- genotype.  Figure 2A shows the weights of spleens from 5 TCL1-
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Tg:p53wt (TCL1-Tg) and 5 TCL1-Tg:p53-/- mice. 17 mice in total 20 TCL1-
Tg:p53-/-  mice developed CLL with early disease onset at the age of 
approximately 3 month, with severe splenomegaly by 4-5 month (Fig 4B).  In 
contrast, the spleens of TCL1-Tg mice with wt p53 or p53+/- mice appeared 
relatively normal in size (Fig 2B).  Histological examination of the spleen 
sections of 4-month old TCL1-Tg mice showed normal tissue architecture, 
whereas the histological sections of the spleen from 4-month TCL1-Tg:p53-/- 
mice showed that the lymphoid follicles were ill-defined (Fig 2C).  The 
germinal centers of the TCL1-Tg:p53-/- spleen exhibited histological features 
reminiscent of the proliferation centers characteristic of CLL/small lymphocytic 
lymphoma because of the presence of large lymphocytes with abundant 
eosinophilic cytoplasm. The red pulps in between the lymphoid follicles 
contained lymphoid cells with more abundant cytoplasm, granulocytes, and 
megakaryocytes compared with red pulps seen in TCL1-Tg mouse spleen 
(Figure 2C). Furthermore, blood smears revealed significant expansion of the 
white blood cells (WBC) in TCL1-Tg:p53-/- mice compared to TCL1-Tg mice 
(Figure 2D). Most of TCL1-Tg:p53-/- mice died at the age of 3-5 months, while 
the most of the TCL1-Tg mice survive more than 12 months (Fig 2E).  This was 
consistent with the clinical observations that CLL patients with 17p deletion 
have significantly shorter overall survival compared to the CLL patients without 
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Figure 2. Characterization of CLL phenotype of TCL1-Tg:p53-/- mice. (A) 
Spleen weights shown for age- and sex-matched TCL1-Tg and TCL1-Tg:p53-/- 
mice at 4 months (n=5 per indicated genotype). **, p<0.01 between group. (B) 
Spleen size shown for age- and sex-matched WT, TCL1-Tg, TCL1-Tg:p53+/- 
and TCL1-Tg:p53-/- mice at 4 months and 5 months old of age (1. WT; 2. TCL1-
Tg; 3. TCL1-Tg:p53+/-; 4. TCL1-Tg:p53-/-). Almost 100% TCL1-Tg:p53-/- mice 
older than 4 months had larger spleen compared to that of TCL1-Tg mice. (n=20 
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Figure 2C. Hematoxylin-eosin (H&E) staining. H&E staining of the spleen 
from TCL1-Tg and TCL1-Tg:p53-/- mice at 4-month of age. Mouse spleen 
tissues were fixed in 10% formalin buffered solution and embedded in paraffin.  
Tissue section from a representative 4-month TCL1-Tg mouse showed normal 
architecture (top panels), while the spleen from a representative TCL1-Tg:p53-/- 
















         
 













Figure 2D. White blood cells (WBC) count. Around 250 µL    blood/mouse was 
collected from mouse tail of 5 mice for each genotype and put in an EDTA-
coated tube. All blood samples were mixed well upon collection. Complete 
Blood Count (CBC) service and WBC differential count service were provided 
by Department of Veterinary Medicine & Surgery Section of Veterinary 
Laboratory Medicine in MD Anderson Cancer Center. WBC count in the 
indicated mouse strains at different ages (n=5 per indicated age). *, p<0.05 

































Figure 2E. Survival curve (Kaplan-Meier) of TCL1-Tg (n=20) and TCL1-
Tg:p53-/- mice (n=33).  Median survival time for the TCL1-Tg:p53-/- mice was 












        Since TCL1-Tg mice show features of human CLL with an increase in 
CD5+/IgM+ B cells in PC, spleen and bone marrow (60), we compared 
CD5+/IgM+ cells in the PC, spleen, and bone marrow of the wild-type mice, 
TCL1-Tg mice, TCL1-Tg:p53+/- mice, and TCL1-Tg:p53-/- mice.  Flow 
cytometry analysis showed that at the age of 4 months, the wild-type mice 
showed 8% CD5+/IgM+ cells in the PC, the TCL1-Tg mice had 21% CD5+/IgM+ 
cells, and the TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice had 35% and 41% 
CD5+/IgM+ cells in the PC, respectively (Figure 3A).  By 5 months, the 
CD5+/IgM+ cells in the PC of TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice 
increased to 58% and 79%, respectively (Figure 3B). In the spleens of a 5-
month old mice, the CD5+/IgM+ cells were undetectable in the wild-type mice, 
7% in TCL1-Tg mice, 15% in TCL1-Tg:p53+/- mice, and 20% in TCL1-Tg:p53-/- 
mice (Figure 3C).  These data seemed consistent with the early onset of CLL in 
TCL1-Tg:p53-/- mice (Figure 2). At 3-5 months, no CD5+/IgM+ cells were 
detected in bone marrow of those mice. No such CD5+/IgM+ CLL population 
was observed in bone marrow of 7-month old TCL1-Tg:p53+/- mice (Figure 3D). 
In the spleens of 4-month old p53-/- mice, the CD5+/IgM+ cells were 
undetectable, and only about 10% CD5+/IgM+ cells were observed in the PC of 
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Figure 3. TCL1-Tg:p53-/- mice had early onset of leukemia and increased 
CD5+/IgM+ B cells compared to TCL1-Tg mice. PC cells and splenocytes were 
isolated and treated with ACK cell lysis buffer for 2 minutes on ice to remove red 
blood cells. After lysis, RPMI medium with 10% FBS was added to the cells to 
stop the lysis. Afterwards, the cells were washed once by PBS and filtered 
through cell strainer with 40 µM nylon mesh for single cell preparation. (A) 
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of PC cells from sex-
matched different mouse strains collected at 4-month old of age (n=4 per 
indicated genotype), and quantitative bar graph shown on the right panel. (B) 
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of PC cells from sex-
matched different mouse strains collected at 5-month old of age (n=4 per 
indicated genotype), and quantitative bar graph shown on the right panel. (C) 
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of splenocytes from 
sex-matched different mouse strains collected at 5-month old of age (n=4 per 









































Figure 3D. Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of 
bone marrow cells from sex-matched different mouse strains collected at 7-
month old of age (n=4 per indicated genotype), and quantitative bar graph 
shown on the right panel. **, p<0.01 between groups.  Bone marrow cells 
were isolated from mouse legs and washed once by PBS and filtered through 
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Figure 3E. Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of 
splenocytes and PC cells from 3 p53-/- mice at 4-month old of age. PC cells 
and splenocytes were isolated and treated with ACK cell lysis buffer for 2 minutes on 
ice to remove red blood cells. After lysis, RPMI medium with 10% FBS was 
added to the cells to stop the lysis. Afterwards, the cells were washed once by 
PBS and filtered through cell strainer with 40 µM nylon mesh for single cell 
preparation. 
 





         4.2 Loss of p53 in CLL cells promotes proliferation and cell survival. 
Recent study suggested that CLL cells in TCL1-Tg mice may undergo 
accelerated cell proliferation accompanied by elevated cell apoptosis, thereby 
displayed a low accumulation of CLL cells and slow disease progression (70).  
Since p53 plays a pivotal role in regulation of cell proliferation and apoptosis in 
response to various stimuli, we examined if a loss of p53 might affect CLL cells 
proliferation in TCL1-Tg mice.  Immunostaining of spleen tissue slides with the 
proliferation marker Ki-67 revealed that Ki67-positive cells were significantly 
higher in the spleens of TCL1-Tg:p53-/- mice compared to that of TCL1-Tg mice 
(Figure 4A, 4C), suggesting an increase in proliferation of the splenocytes in 
TCL1-Tg:p53-/- mice.  We then used TUNEL assay to compare in vivo apoptosis 
of splenocytes in TCL1-Tg and TCL1-Tg:p53-/- mice.  TUNEL staining of the 
spleen tissue sections showed that TCL1-Tg:p53-/- mice had significantly less 
apoptotic cells in the spleen compared to that in the spleen of TCL1-Tg mice 
(Figure 4B, 4D). Consistently, annexin-V/PI double-staining of the splenocytes 
revealed that the isolated splenocytes from TCL1-Tg:p53-/- mice were less 
apoptotic when cultured in vitro for 24-72 h compared to the splenocytes 
isolated from TCL1-Tg mice culture under identical conditions (data not shown). 
Taken together, these data suggest that the loss of p53 in TCL1-Tg mice seems 
to promote cell proliferation and decrease apoptosis.  This might account for the 
much higher accumulation of CLL cells and rapid disease progression in TCL1-








































Figure 4. P53 deficiency increased cell proliferation and elevated cell 
survival of leukemia cells from TCL1-Tg:p53-/- mice. (A) Mouse splenic 
sections were stained with the proliferation marker Ki-67 for age and sex-
matched TCL1-Tg and TCL1-Tg:p53-/- mice. (B) Left panel, apoptosis in splenic 
sections shown by staining with TUNEL-TMR-Red. Right panel, DAPI staining 
indicates nuclear staining of total cells. (C) Statistic analysis of the results for A 
showed average of Ki67-positive cells/field from splenic sections, respectively 
(n=3 per group). *, p<0.05, **, p<0.01 between groups. (D) Statistic analysis of 
the results for B showed average of TUENL-positive cells/field from splenic 









         4.3 Leukemia cells from TCL1-Tg:p53-/- mice or from CLL patients 
with 17p deletion are resistant to chemotherapeutic drugs. The observations 
that the leukemia cells isolated from TCL1-Tg:p53-/- mice exhibited less 
spontaneous apoptosis (Fig 4B, 4D) prompted us to speculate that the leukemia 
cells with loss of p53 might be less sensitive to apoptotic induction and thus 
might be more resistant to chemotherapeutic agents.  To test this possibility, we 
isolated splenocytes from the wild-type control mice and from TCL1-Tg, TCL1-
Tg:p53+/- and TCL1-Tg:p53-/- mice, and then treated the cells with several 
standard anti-CLL chemotherapeutic agents in culture (114).  As shown in 
Figure 5, the splenocytes from the control and TCL1-Tg mice exhibited similar 
sensitivity to F-ara-A (active form of fludarabine, 10 M), chlorambucil (10 
M), and oxaliplatin (10 M). The loss of one p53 allele (TCL1-Tg:p53+/-) 
caused a moderate decrease in drug sensitivity, whereas the loss of both p53 
alleles (TCL1-Tg:p53-/-) led to a significant resistance to all three 















             
 
 




















Figure 5. P53 deletion makes mouse leukemia cells more resistant to 
standard CLL drug treatment. Splenic cells from indicated mouse strains 
were cultured in RPMI1640 medium with 10% FBS plus 1% PS and treated 
with 10uM F-ara-A, Chlorambucil and Oxaliplatin for 48h, and Annexin V-PI 








        To further confirm the correlation between the loss of p53 and drug 
resistance in primary CLL cells from patients, we compared the drug sensitivity 
of primary leukemia cells from CLL patients with or without 17p deletion.  
Flow cytometry analysis showed that CLL cells isolated from patients without 
17p deletion were sensitive to F-ara-A (10µM) and oxaliplatin (10µM), which 
caused a loss of 40-50% cell viability during the 48-h drug incubation (Figure 
6). For instance, in patient #1 the control cell showed 78% viability, and drug 
treatment led to a substantial decrease of viable cells (37-41%).  Similar results 
were observed in CLL cells from patient #2.  In contrast, CLL cells with 17p 
deletion were highly resistant to F-ara-A and oxaliplatin (Figure 6, patients #3 
& #4).  For instance, in CLL sample #4, the control sample without drug 
treatment showed 87% viable cells.  After treatment with F-ara-A or oxaliplatin, 
the cell viability remained at 85-86%.  Similar drug resistance was observed in 
patient sample #3.  Treatment resistance was also observed in other patient 
samples with 17p deletion (patients #8 to #10) as shown in Figure 7. The Figure 
8 showed similar drug resistance of 17p- B cells isolated from primary CLL 
cells. The results from experiments with leukemia cells from mice and from 
CLL patients consistently suggest that the loss of p53 leads to the drug 
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Figure 6. P53 deletion makes human leukemia cells more resistant to 
standard CLL drug treatment.  White blood cells were isolated from CLL 
patients’ blood and cultured in RPMI1640 medium containing 10% FBS and 
1% PS. CLL patient samples with 17p WT (Pt #1 & Pt #2) or with >70% 17p 
deletion (Pt #3 & Pt #4) were treated with 10uM F-ara-A and 10uM Oxaliplatin 
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Figure 7. For more patient samples, p53 deletion makes leukemia cells 
more resistant to standard CLL drug treatment.  CLL patient samples with 
17p WT (Pt #5-7) or with 17p deletion (Pt #8-10) were treated with 10uM F-
ara-A and 10uM Oxaliplatin for 48h, respectively. Cell apoptosis was analyzed 
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Figure 8. P53 deletion makes human leukemia B cells more resistant to standard 
CLL drug treatment.  White blood cells were isolated from CLL patients’ blood and 
cultured in RPMI1640 medium containing 10% FBS and 1% PS. CD19 positive B cells 
purified from CLL patient samples with 17p WT (Pt A-C) or with 17p deletion (Pt D-F). 
After purification, B cells were treated with 10uM F-ara-A and 10uM Oxaliplatin for 











          4.4 Loss of p53 in CLL cells promotes Mcl-1 expression associated 
with down-regulation of miR-15a and miR-16-1. To investigate the 
mechanisms that contribute to the drug resistant phenotype in CLL cells lacking 
p53, we first compared the expression of the anti-apoptotic Bcl-2 family 
members including Bcl-2, Mcl-1, and Bcl-XL in CLL cells isolated from the 
spleens and PCs of the TCL1-Tg and TCL1-Tg:p53-/- mice.  Western blot 
analysis showed that the expression of these anti-apoptotic molecules increased 
to various degrees in the p53-null cells (Figure 9A), with the elevation of Mcl-1 
protein being the most prominent event, which was detected in leukemia cells 
isolated from spleen and PC.  Bcl-XL protein levels were also increased in both 
the splenocytes and PC cells from TCL1-Tg:p53-/- mice compared to TCL1-Tg 
mice.  Interestingly, the increased Bcl-2 was observed in the peritoneal 
leukemia cells but not in splenocytes (Figure 9A).  Real-time RT-PCR analysis 
showed a significant increase in mRNA expression of Mcl-1, Bcl-XL, and Bcl-2 
in the splenocytes and PC cells from TCL1-Tg:p53-/- mice compared to those 
from TCL1-Tg mice (Figures 9B-9D).  Importantly, the increase in Mcl-1, Bcl-
XL, and Bcl-2 protein expression was also observed in primary CLL cells 
isolated from patients with 17p deletion (Figure 10A).  Such increase was 
consistently observed in multiple patient samples.  Real-time RT-PCR analysis 
showed that the mRNA expression of these 3 molecules was also increased in 
CLL cells with 17p deletion (Fig 10B).  These data together suggest that the 
increased expression of Bcl-2 family members occurred mainly at 
transcriptional level.  Consistently, both protein and mRNA levels of Mcl-1 and 
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Bcl-XL were increased in 17p- B cells isolated from patient CLL cells (Figure 
11 & Figures 12A-12B). Interestingly, the increased Bcl-2 expression was 



























                                 A 
Spleen Peritoneal 
                            
Mcl-1 
 β-actin 
    p53:   +/+    -/-      +/+     -/-  
Bcl-XL 
Bcl-2 




















Figure 9. Bcl-2 survival family gene expression in mouse splenocytes and 
PC cells isolated from TCL1-Tg and TCL1-Tg:p53-/- mice. (A) Mcl-1, Bcl-
XL and Bcl-2 protein expression shown by Western blot analysis. (splenocytes 
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Figure 9. Bcl-2 survival gene expression in cells from TCL1-Tg and TCL1-
Tg:p53-/- mice. (B) Mcl-1 mRNA levels in mouse splenocytes and PC cells 
shown by RT-PCR (n=4 per indicated strain). *, p<0.05, **, p<0.01 between 
groups. (C) Bcl-XL mRNA levels in mouse splenocytes and PC cells shown by 
RT-PCR (n=4 per indicated strain). *, p<0.05, **, p<0.01 between groups. (D) 
Bcl-2 mRNA levels in mouse splenocytes and PC cells shown by RT-PCR (n=4 
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Figure 10.  Bcl-2 survival family gene expression in CLL cells from human 
patient samples with 17p deletion or with 17p wt. (A) Western blot analysis 
showed Mcl-1, Bcl-XL and Bcl-2 protein levels in CLL cells from human CLL 
patient samples with or without 17p deletion (4 >70% 17p deletion samples: 
del1-4; 6 17p WT samples: WT1-6). (B) Mcl-1, Bcl-XL and Bcl-2 mRNA 
levels in CLL cells from human patients with or without 17p deletion shown by 













































Figure 11. Bcl-2 survival family gene expression in CLL-B cells from 
patient samples with 17p deletion or with 17p wt. Western blot analysis 
showed Mcl-1, Bcl-XL and Bcl-2 protein levels in CD19 positive B cells from 
human CLL patient samples with or without 17p deletion (3 17p WT samples 


























Figure 12.  mRNA levels of Bcl-2 survival family in CLL-B cells from 
patient samples with 17p deletion or with 17p wt. (A) Mcl-1 mRNA levels in 
CD19 positive B cells from human CLL patient samples with or without 17p 
deletion (3 17p WT samples and 4 17p- samples). (B) Bcl-XL mRNA levels in 
CD19 positive B cells from human CLL patients with or without 17p deletion (3 
17p WT samples and 4 17p- samples). (C) Bcl-2 mRNA levels in CD19 positive 
B cells from human CLL patients with or without 17p deletion (3 17p WT 












To further investigate the possible mechanisms by which loss of p53 led 
to increased expression of multiple Bcl-2 family members, we speculated that 
since the expression of Bcl-2 multiple family members is known to be regulated 
by certain microRNAs (miR15a, miR-16) (115), it is possible that the loss of 
p53 might cause a decrease expression of some specific microRNAs, leading to 
over-expression of Mcl-1, Bcl-XL, and Bcl-2.  To test this possibility, we first 
isolated total RNA from the splenocytes of TCL1-Tg and TCL1-Tg:p53-/- mice, 
and explored the expression profiles of microRNAs.  Among the >300 
microRNAs detected, miR-15a and miR-16-1 were markedly decreased in 
TCL1-Tg:p53-/- mice compared to that of TCL1-Tg mice.  The decrease of miR-
15a and miR-16-1 in cells from TCL1-Tg:p53-/- mice was further confirmed by 
real-time RT-PCR using the leukemia cells isolated from the spleens and PCs of 
TCL1-Tg and TCL1-Tg:p53-/- mice.  As shown in Figure 13A, there was a 
significant decrease in the expression of miR-15a and miR-16-1 in both 
splenocytes and PC cells from mice without p53.  Importantly, the decrease in 
miR-15a/16 expression was further confirmed in primary CLL cells isolated 
from patients with 17p deletion (Figure 13B).   Consistently, similar results 
were observed in B cells isolated from primary CLL cells (Figure 14). These 
data together suggest that suppression of miR15a/miR16-1 expression may be 
an important mechanism by which the loss of p53 enhances the expression of 



















Figure 13. Expression of tumor suppressor miR-15a/16-1 in mouse and 
human leukemia cells. (A) MiR-15a/16-1 expression in mouse splenocytes and 
PC cells shown by RT-PCR. *, p<0.05, **, p<0.01 between groups. (B) MiR-
15a/16-1 expression in CLL cells from patient samples with or without 17p 
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Figure 14. MiR15a/16-1 expression in CLL-B cells. (A) MiR-15a expression 
in CD19 positive B cells purified from patient samples with or without 17p 
deletion shown by RT-PCR (3 17p WT samples and 4 17p- samples). (B) MiR-
16-1 expression in CD19 positive B cells purified from patient samples with or 












        4.5 Loss of p53 in CLL cells causes down-regulation of miR-30 family, 
leading to upregulation of downstream oncogenes EZH2 and B-Myb. In 
addition, among the >300 microRNAs detected, miR-30a, miR-30e, and 
particularly miR-30d were markedly decreased in TCL1-Tg:p53-/- mice 
compared to that of TCL1-Tg mice.  The downregulation of miR-30 family in 
cells from TCL1-Tg:p53-/- mice was further confirmed by real-time RT-PCR 
using the leukemia cells isolated from the spleens and PCs of TCL1-Tg and 
TCL1-Tg:p53-/- mice.  As shown in Figure 15A, there was a significant decrease 
in the expression of miR-30 family in both splenocytes and PC cells from mice 
without p53.  Importantly, the decrease in miR-30 family expression was further 
confirmed in primary CLL cells isolated from patients with 17p deletion (Figure 
15B).  It has been reported that miR-30d targets EZH2 which is involved in 
repressing gene expression through methylation of histone H3 on lysine 27 and 
upregulated in anaplastic thyroid carcinomas (90). Over years, many studies 
have established that EZH2 is overexpressed in various cancers including some 
hematologic malignancies, and such overexpression is associated with 
aggressive disease progression (91, 92). The role of EZH2 in CLL has yet to be 
examined in vitro and in vivo. Another target of miR-30 is B-Myb, which 
expression can be regulated by miR-30 and miR-29 during cellular senescence 
(95). B-Myb, a transcription factor, is involved in cell proliferation and 
transcription and carcinogenesis. B-Myb overexpression presents in various 
cancers and is associated with aggressive tumor growth and poor outcomes (96-
98). However, the role of B-Myb in CLL is still unknown. Both EZH2 and B-
 77
Myb are upregulated in mouse CLL cells with p53 deletion as shown in Figure 
16.  The EZH2 inhibitor 3-deazaneplanocin (DZNep) led to induction of more 
apoptosis in splenocytes isolated from TCL1-Tg:p53-/- mice compared to that of 
TCL1-Tg mice (Figure 17). Taking together, this study provides evidence to 
support the important role of p53miR30dEZH2 & B-Myb axis in the 
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Figure 15. Expression of tumor suppressor miR-30 family in mouse and 
human leukemia cells. (A) MiR-30a, miR-30d and miR-30e expression in 
mouse splenocytes and PC cells shown by RT-PCR. *, p<0.05, **, p<0.01 
between groups. (B) MiR-30a, miR-30d and miR-30e expression in CLL cells 
from human patient samples with or without 17p deletion shown by RT-PCR. *, 
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   Figure 16. Expression of EZH2 and B-Myb in mouse and human CLL 
cells. (A) Expression of EZH2 and B-Myb in splenocytes from 3 TCL1-Tg mice, 
3 TCL1-Tg:p53+/- mice, and 6 TCL1-Tg:p53-/- mice. (B) Expression of EZH2 








































Figure 17. DZNep treatment in mouse splenocytes. Splenic cells from 3 
TCL1-Tg and 3 TCL1-Tg:p53-/- mice were cultured in RPMI1640 medium with 
10% FBS plus 1% PS and treated with 3uM SAHA, 3uM 3-DEZNP, 10uM F-
ara-A or their combination for 48h. PEITC treatment was only 4 h. Annexin V-












        4.6 New compound NL-101 induces significant apoptosis in CLL cells 
with or without p53 deficiency. Despite of the fact that various advanced 
therapeutic strategies have improved the CLL treatment in clinic, the disease is 
not cured yet. As shown in Figures 5-8, CLL cells with p53 deficiency were 
resistant to conventional CLL chemotherapies such as F-ara-A. Therefore it is 
urgent to study new therapeutic strategies for the treatment of the subtype of 
CLL with p53 deficiency. It was observed that new compound NL-101 induced 
significant apoptosis in CLL cell with 17p wt (Figure 18). NL-101 contains both 
the HDACI-SAHA and the alkylating agent-Bendamustine moieties in 1:1 ratio. 
48h treatment of 3µM NL-101 induced around 85% apoptosis in CLL cells 
cocultured with NKTert cells. 48h treatment of 3µM SAHA only induced about 
75% apoptosis in the CLL cells when cocultured with stromal cells NKTert. 
However, 10µM Bendamustine didn’t induce any apoptosis in the CLL cells 
cocultured with NKTert cells. The combination of 3µM SAHA + 10µM 
Bendamustine almost killed all CLL cells even cocultured with NKTert cells. 
Without coculture, those compounds only or their combination efficiently 
induced apoptosis in the CLL cells (Figure 18A). The bar graph in Figure 18B 
showed efficient killing effect of NL101 or SAHA combined with alkylating 
agents in CLL cells with or without coculture with stromal cells. Interestingly, 
NL-101 and PEITC both can induce significant apoptosis in CLL cells with 17p 
deletion (Figure 19). As mentioned before, a subtype of CLL with chromosome 
17p deletion is associated with accelerated disease progression, drug resistance, 
and poor prognosis due to loss of p53 gene (100). In our studies, we observed 
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that 4h 10µM PEITC treatment or 48h 6µM NL-101 treatment only induced 
significant apoptosis in the subtype of CLL cells with 17p deletion with or 
without coculture with stromal NKTert cells. Similarly SAHA combined with 
Chlorambucil or Bendamustine also induced significant apoptosis in this 
subtype of CLL with or without coculture with stromal NKTert cells. The NL-
101 compound combined with PEITC almost killed all of this subtype of CLL 
cells as shown in Figure 21. Consistently the compound NL-101 also induced 
significant apoptosis in mouse CLL cells when cocultured with stromal cells. 
Interestingly not only NL-101 treatment but also SAHA treatment only induced 
significant apoptosis in mouse splenocytes isolated from TCL1-Tg and TCL1-
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Figure 18. NL-101 treatment in human CLL cells with 17p wt. White blood 
cells were isolated from CLL patients’ blood and cultured in RPMI1640 
medium containing 10% FBS and 1% PS. (A) CLL patient samples with 17p wt 
were treated with 3uM NL-101, 3uM SAHA, 10uM Bendamustine and 3uM 
SAHA+10uM Bendamustine for 48h when cocultured with human stromal cells 
NKTert or without coculture. Cell apoptosis was analyzed by Annexin V-PI 
staining. (B) The quantitative bar graph showed the treatment results analyzed 
by Annexin V-PI staining in human CLL cells cocultured with stromal cells 






























Figure 19. NL-101, PEITC and other treatments in human CLL cells with 
17p deletion 7. White blood cells were isolated from CLL patients’ blood and 
cultured in RPMI1640 medium containing 10% FBS and 1% PS. CLL patient 
samples with 17p deletion were treated with 3uM SAHA, 10uM Chlorambucil, 
20uM Bendamustine, 10uM F-ara-A, 6uM or 10uM NL-101 and their 
combinations for 48h with or without coculture with stromal NKTert cells. 





































Figure 20. NL-101 treatment in mouse CLL cells with or without p53 
deficiency. Splenic cells from  TCL1-Tg and TCL1-Tg:p53-/- mice were cultured 
in RPMI1640 medium with 10% FBS plus 1% PS and treated with 10uM F-ara-
A or Chlorambucil, 20uM Bendamustine, 3uM SAHA or SAHA combined with 
the alkylating agents and 3uM NL-101 for 48h when cocultured with stromal 
Kusa.H1 cells. Annexin V-PI analysis by FACS was performed to detect 














        4.7 NL-101 and PEITC treatment prolonged the survival time for 
TCL1-Tg:p53-/- mice. Since we observed efficient killing effects of NL-101 and 
PEITC in CLL cells with p53 deficiency in vitro, the NL-101 and PEITC 
treatment in vivo were performed using intravenous injection (i.v. injection). 
Tail inflammation was observed after 6 times of iv injection for some TCL1-
Tg:p53-/- mice. As shown in Figure 21, only 6 times i.v. injection of NL-101 
prolonged the survival time of TCL1-Tg:p53-/- mice. PEITC treatment 







































Figure 21. Survival curve (Kaplan-Meier) of TCL1-Tg:p53-/- mice treated 
with NL-101 or PEITC (n=20 per group).  NL-101 treatment plan: 2 
times/month i.v. injection of 6mg/ml for 3 months; PEITC treatment plan: i.v. 















        4.8 Underlying mechanisms of NL-101 induced apoptosis in CLL cells. 
After observing significant killing effect of NL-101 in CLL cells, we 
hypothesized that the HDACI-moiety of NL-101 can overcome resistance of the 
alkylating agent-moiety in CLL treatment. More DNA strand breaks were 
observed in CLL cells treated with NL-101 only or SAHA combined with 
Bendamustine than Bendamustine treatment only analyzed by comet assay 
(Figure 22). In addition, HDACI such as SAHA can overcome resistance of 
alkylating agents in CLL treatment by reducing CXCL12 secreted from stromal 
cells. RT-PCR experiments showed reduced levels of CXCL12 in stromal 
NKTert cells treated with HDACI or NL-101 (Figure 23). In Figure 24, ELISA 
assay showed significant decrease of CXCL12 levels in Kusa.H1 and NKTert 
cells treated by HDACI such as SAHA and LBH. Interestingly the CXCL12 


































Figure 22. DNA strand breaks in CLL cells analyzed by Comet assay. CLL 
cells were treated with 3µM SAHA, 3µM NL-101, 20µM Bendamustine or 
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Figure 23. CXCL12 mRNA levels in NKTert cells treated with HDACI, 
HDACI combined with alkylating agents or NL-101 analyzed by RT-PCR. 
1X105 NKTert cells were seeded in a 6-well plate. The HDACI or NL-101 
treatment was performed when the cells were 70% confluent. 48h later, the cells 


























Figure 24. CXCL12 levels in stromal HS5, Kusa.H1 and NKTert cells 
treated with SAHA or LBH determined by ELISA assay. 6X105 HS5 cells, 
1X104 Kusa.H1 cells and 4X104 NKTert cells were seeded in 24-well plates 
with RPMI1640 medium at day 1. At day 3, the medium was removed and 
500µL fresh medium was added for each well. HDACI treatment was 













         Recent progress in investigation of CLL biology and the development of 
new therapies such as F-ara-A-based regimens has led to significant 
improvements of therapeutic outcomes. However, many CLL patients, 
particularly those with loss of p53 function due to chromosome 17p deletion 
and p53 mutations, are refractory to the current therapeutic regimens with poor 
prognosis (56).  Loss of p53 function can be due to deletion or mutations of the 
gene that encodes for p53, epigenetic silencing, and functional inactivation.  In 
CLL, chromosome 17p deletion and p53 mutations are well-documented 
mechanisms that lead to loss of p53 function associated with poor prognosis (56, 
116). The exact mechanisms by which loss of p53 may lead to aggressive 
disease progression and poor clinical outcomes in CLL remain illusive. Based 
on the important role of p53 in cell cycle control and regulation of apoptosis 
(117), it is generally speculated that loss of p53 function may result in 
impairment of cycle-cycle checkpoints and compromised apoptotic response, 
leading to disease progression and drug resistance.  However, there is no 
conclusive evidence in vivo to support this notion, perhaps in part due to the 
lack of proper CLL animal model with loss of p53.   
        5.1 Rapid disease progression and treatment resistance 
occurred in TCL1-Tg:p53-/- mice. In the present study, we generated a mouse 
colony with TCL1-Tg:p53-/- genotype, and demonstrated that these mice 
developed leukemia that resembles aggressive human CLL.  The TCL1-Tg:p53-
/- mice exhibited signs of CLL disease around 3 months, with early appearance 
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of CD5+/IgM+ cells in the PC and spleen. Most TCL1-Tg:p53-/-  mice showed 
highly abnormal accumulation of WBC in the blood and developed severe 
splenomegaly at 3-4 month, and died before 6 months.  This is in contrast with 
the TCL1-Tg mice, which develop CLL approximately at the age of 1 year, and 
the disease progresses slowly (60).  In the TCL1-Tg:p53-/- mice, we observed a 
significant increase in lymphoid cell proliferation in the spleen and a decrease in 
apoptosis.  This may explain why these mice had severe accumulation of 
leukemia cells and enlargement of the spleen at early age. The control p53-/- 
mice didn’t accumulate much leukemia cells at 4-month old of age, however, 
our mouse model exhibited significant higher number of leukemia cells,  
suggesting that TCL1-Tg:p53-/- mice had specific CLL features rather than 
lymphoma occurring in p53-/- mice. Since p53 plays a key role in enhancing the 
expression of apoptotic molecules such as Bax and PUMA (118), loss of p53 
function would significantly compromise this apoptotic pathway, leading to 
resistance to chemotherapeutic agents.  In fact, we observed that the leukemia 
cells isolated from TCL1-Tg:p53-/- mice or from CLL patients with 17p deletion 
were highly resistance to standard anti-CLL drugs F-ara-A and oxaliplatin. 
Furthermore, CD19 positive B cells purified from CLL patients with 17p 
deletion were highly resistance to F-ara-A and oxaliplatin. To overcome 
treatment resistance, new therapeutic strategies need to be applied in clinic such 
as PEITC and NL-101 compound. 
        5.2 Up-regulated Mcl-1 in leukemia cells with p53 deletion. An 
important observation in this study was the significant up-regulation of Mcl-1 
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expression in the leukemia cells lacking p53.  This was seen both in the 
leukemia cells from the TCL1-Tg:p53-/- mice and in primary CLL cells from 
patients with 17p deletion (Figure 9 & 10).    Mcl-1 is a key anti-apoptotic 
protein in the Bcl-2 family, and this molecule is known to be particularly 
important for the survival of CLL cells (85).  Thus, upregulation of Mcl-1 may 
play a major role in apoptosis resistance in CLL cells lacking p53, and the 
moderate increase in Bcl-XL and Bcl-2 expression may also contribute to the 
increased viability of leukemia cells in TCL1-Tg:p53-/- mice. Since the increase 
in Mcl-1 expression was observed at mRNA and protein levels, it is likely that 
loss of p53 may promote Mcl-1 expression mainly at the transcriptional level.  
This is consistent with the observation that p53 transcriptionally represses Mcl-
1 (119-122).   
5.3 Down-regulated miR-15a/miR-16-1 in leukemia cells with p53 
deletion. Interestingly, the miRNA expression levels of miR15a and miR-16-1 
were significantly decreased in CLL cells with loss of p53.  This was observed 
both in the TCL1-Tg:p53-/- mouse model and in primary CLL cells isolated from 
patients with 17p deletion. Because Mcl-1 is a target of miR-15a and miR-16-1 
(123, 124), the decrease in these miRNAs would release their suppression on 
Mcl-1 and thus lead to its elevated expression.  Thus, it is possible that p53 
might regulate Mcl-1 expression through modulating miR15a/16.  It has been 
shown previously that miRNAs may be involved in CLL pathogenesis and 
prognosis due to their function as oncogenes or tumor suppressors (102). For 
example, miR-15a/miR-16-1 is located in chromosome 13q14.3, a region that is 
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frequently mutated or deleted in CLL patients and may affect CLL cell survival 
and drug resistance (115).  Intriguingly, p53 may regulate the expression of 
multiple miRNAs, many of which are closely involved in cell cycle regulation, 
proliferation and apoptosis (104). Our initial study using miRNA array to 
examine the effect of loss of p53 on miRNA expression in the TCL1-Tg:p53-/- 
mice had identified miR-15a and miR-16-1 being significantly down-regulated, 
which was further validated by real-time RT-PCR. Clearly, miR-15a/16-1 
expression is significantly lower in splenocytes and PC cells from TCL1-
Tg:p53-/- mice than that of TCL1-Tg mice. These observations together suggest 
that p53miR-15a/16-1Mcl-1 axis may be an important pathway in 
regulating CLL cell apoptosis and drug resistance. The important role of the 
p53miR-15a/16-1Mcl-1 axis in the development of aggressive CLL merits 
further investigation in clinical setting.  
5.4 Down-regulated miR-30d in leukemia cells with p53 deletion. 
Our initial study using miRNA array to examine the effect of loss of p53 on 
miRNA expression in the TCL1-Tg:p53-/- mice had identified miR-30a, miR-
30e and particularly miR-30d being significantly down-regulated, which was 
further validated by real-time RT-PCR. Clearly, miR-30a/miR-30d/miR-30e 
levels were significantly lower in splenocytes and PC cells from TCL1-Tg:p53-/- 
mice than that of TCL1-Tg mice. It has been reported that EZH2 and B-Myb are 
targets of miR-30 family (90, 95). Since we observed significant up-regulation 
of EZH2 and B-Myb in leukemia cells with p53 deletion, p53miR-
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miR30EZH2 & B-Myb axis may be another important pathway in regulating 
CLL cell apoptosis and drug resistance.  
 
6. SUMMARY AND CONCLUSIONS 
The whole study can be summarized in the following diagram.  I have 
generated TCL1-Tg:p53-/- mice, which develop aggressive CLL with an early 
disease onset, likely due to increase proliferation of the leukemia cells and 
decrease in apoptosis.  The CLL cells lacking p53 exhibited low sensitivity to 
standard anti-CLL drugs. In our study, we tested new compound NL-101 and 
PEITC in our mouse model. It has been reported that PEITC effectively 
eliminates F-ara-A-resistant CLL cells through ROS accumulation and 
glutathione depletion (45). We observed that PEITC was very efficient to 
eliminate CLL cells both in vitro and in vivo. The underlying mechanism for 
efficient killing effect of NL-101 in CLL is possible through HDAC inhibitor-
overcoming the treatment resistance of alkylating agents by inhibiting CXCL12 
and inducing more DNA damage to CLL cells. Our study also provided in vivo 
evidence that loss of p53 led to upregulation of Mcl-1 expression, probably 
though the down regulation of miR-15a and miR-16-1 and thus released their 
suppression on Mcl-1 expression. Another possibility is that p53 
transcriptionally represses Mcl-1, leading to decrease in apoptosis and drug 
resistance in CLL cells from TCL1-Tg:p53-/- mice. Furthermore, loss of p53 
cause down-regulation of miR-30 family especially miR-30d which regulates 
up-regulation of EZH2 & B-Myb, probably leading to rapid disease progression 
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and treatment resistance in leukemia cells lacking p53. The TCL1-Tg:p53-/- 
mouse colony may serve as a valuable mouse model to further investigate the 
pathogenesis of aggressive CLL due to loss of p53 function.  In addition, since 
these mice develop leukemia at early age and die within 6 months, this animal 
model may be useful in testing new drugs for their in vivo therapeutic activity 
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